Search research articles
Contact Us
Filters
Showing results (31-40 of 43) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
March 5, 2026
ISDE guidelines on the management of cT2N0 esophageal cancer
Geoffrey P Kohn, Virginia Litle, Yousif Eliya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Lavinia Tan, Ben Tran, Jeanne Tie, et al.
British Journal of Cancer
|
September 21, 2023
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
Daphne Day, John J Park, Jermaine Coward, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard, Jair Bar, Pilar Garrido, et al.
JTO Clinical and Research Reports
|
October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Quincy Chu, Natasha B Leighl, Veerle Surmont, et al.
Journal for Immunotherapy of Cancer
|
June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
Journal of Cancer Policy
|
November 26, 2023
A tailored approach to horizon scanning for cancer medicines
Jennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 43) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Sylvie Rottey, Jeffrey Clarke, Kyaw Aung, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus
|
March 5, 2026
ISDE guidelines on the management of cT2N0 esophageal cancer
Geoffrey P Kohn, Virginia Litle, Yousif Eliya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2023
A Phase Ib/II Trial of Combined BRAF and EGFR Inhibition in BRAF V600E Positive Metastatic Colorectal Cancer and Other Cancers: The EVICT (Erlotinib and Vemurafenib In Combination Trial) Study
Lavinia Tan, Ben Tran, Jeanne Tie, et al.
British Journal of Cancer
|
September 21, 2023
A first-in-human phase 1 study of nofazinlimab, an anti-PD-1 antibody, in advanced solid tumors and in combination with regorafenib in metastatic colorectal cancer
Daphne Day, John J Park, Jermaine Coward, et al.
The Lancet. Gastroenterology & Hepatology
|
February 5, 2018
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
Derek J Jonker, Louise Nott, Takayuki Yoshino, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 18, 2020
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai, Hui Gan, Catherine Barrow, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 28, 2022
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study
Nicolas Girard, Jair Bar, Pilar Garrido, et al.
JTO Clinical and Research Reports
|
October 24, 2022
BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/Refractory SCLC: Results From a First-in-Human Phase 1/2 Study
Quincy Chu, Natasha B Leighl, Veerle Surmont, et al.
Journal for Immunotherapy of Cancer
|
June 17, 2020
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
Jayesh Desai, Sanjeev Deva, Jong Seok Lee, et al.
Journal of Cancer Policy
|
November 26, 2023
A tailored approach to horizon scanning for cancer medicines
Jennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Page
of 5